CVS Health Corp (NYSE:CVS) reported better-than-expected financial results for the second quarter, driven by robust growth across its retail pharmacy, insurance (Aetna), and health services segments.
Total revenue was up 8.4% at $98.9 billion, above Wall Street estimates of $94.7 billion.
Adjusted earnings per share (EPS) of $1.81 beat estimates of $1.46.
The company also raised its adjusted EPS guidance for the full year to a range of $6.40 to $6.40 from its earlier guidance range of $6 to $6.20.
It also now expects cash flow from operations guidance to at least $7.5 billion from approximately $7 billion.
"We are encouraged by a second consecutive quarter of solid 2025 results, while we continue to navigate a dynamic environment," CVS Health CFO Brian Newman said.
"As we execute against our strategic priorities, we remain focused on delivering on our financial commitments and advancing initiatives that create long-term value for our stakeholders."
CVS Health CEO David Joyner added: “Our strong performance demonstrates the continued focus we have on operational and financial improvement across our businesses, led by a significant and durable recovery at Aetna, strong retention at CVS Caremark and growth and momentum at CVS Pharmacy.”
Shares of CVS Health added 1.3% at $63 post-earnings.